SWK Holdings Corporation (SWKH)

Over the past six months, SWK Holdings Corp.'s stock price has been impacted by several events. These include a strong Q3 2025 earnings report, acquisition discussions with Runway Growth Finance (and a related investigation), a downgrade by Maxim Group, a strategic shift involving royalty asset sales and a special dividend, a Q2 2025 earnings report detailing asset sales and share repurchases, and a Q4 2024 portfolio update. As of November 21, 2025, the stock price was $16.65, representing a 4.78% increase from the previous year, with a trading range between $13.17 and $20.49.

Information regarding the specific demand seasonality for SWK Holdings Corp.'s products and services is not readily available. The nature of specialized finance and pharmaceutical development may not exhibit strong seasonal patterns.

SWK Holdings Corporation is a specialized finance company focused on providing capital solutions to the global healthcare and life sciences sectors. The company offers structured debt and royalty monetization, maintains an investment portfolio, provides advisory services, and engages in pharmaceutical development through its subsidiary, Enteris BioPharma, utilizing its Peptelligence platform.

SWK Holdings Corporation is headquartered in Dallas, Texas, United States. The company's client base primarily spans the United States, with some engagement in international markets where healthcare and life science innovations are prevalent.

SWK Holdings generally has a positive brand reputation, with partners describing the company as a strong and professional partner that provides flexible capital solutions. However, an investigation by Halper Sadeh LLC regarding the fairness of the sale of SWK Holdings Corporation to Runway Growth Finance Corp. could potentially affect its reputation.

The ownership structure of SWK Holdings includes institutional investors, insiders, public companies, and individual (retail) investors. Institutional investors hold approximately 83.46% to 86.15% of the stock, with major holders including Carlson Capital L.P., M3F, Inc., and Vanguard Group Inc. Insiders own approximately 1.52% of the stock, while public companies and individual investors own approximately 2.69% to 12.34%.